BioNTech SE is a German clinical biotechnology company. The company focuses on providing immunotherapy for patients to treat cancer and other serious diseases. The company has developed a wide range of product lines by using various scientific methods and technical platforms, including candidate products based on individual mRNA, chimeric antigen receptor T cells, checkpoint immunomodulators, cancer-targeting antibodies and small molecules. In addition, the company also provides diagnostic products and drug development services for other therapeutic areas such as infectious diseases, allergies and autoimmune diseases.
Extended data:
Founded in 2008, BioNTech has been committed to pioneering research and development of new therapeutic drugs for cancer and other serious diseases, exploring a large number of platforms for calculating R&D and therapeutic drugs, and rapidly developing new biopharmaceutical products. Company investors include venture capital firm MIG AG, German generic drug manufacturer Hexal AG founder Struengmann brothers and Bill and Melinda? Gates foundation, etc.
COVID-19's transformation from anti-cancer drugs to vaccine research and development stems from a scientific paper on the COVID-19 epidemic that Dr. Shaheen read in June+10 this year. At that time, he judged that COVID-19 might develop into an epidemic, and the mRNA research used in anticancer drugs could also be used to develop an mRNA COVID-19 vaccine.
People's Network-The effective rate of candidate vaccines of Pfizer and BioNTech is 90%.